Plasma Donations Needed to Support Development of Treatments for COVID-19
The U.S. Food & Drug Administration (FDA) is calling upon those who have recovered from COVID-19 to donate blood plasma to assist in the development of a possible treatment for the disease.
Convalescent plasma contains antibodies, and in this case, COVID-19 antibodies that may help other patients recover. Donations must come from patients who are eligible to donate blood, have received a positive laboratory test for COVID-19, have had an absence of symptoms for at least two weeks, and have received a negative lab test for COVID-19 to prove their recovery. Individuals may donate at numerous blood donation centers, including the CoVig-19 Plasma Alliance. This alliance is comprised of leading pharmaceutical companies including Takeda, a Council member. The companies are focused on developing a plasma therapy derived from the polyclonal anti-SARS-CoV-2 hyperimmune globulin CoVig-19. The treatment will help protect at risk individuals and healthcare workers from pulmonary lung disease and life-threatening complications of COVID-19.
“Unprecedented times call for bold moves,” said Julie Kim, the President of Plasma-Derived Therapies Business Unit at Takeda. “We collectively agree that by collaborating and bringing industry resources together, we could accelerate bringing a potential therapy to market as well as increase the potential supply. We invite companies and institutions focusing on plasma to support or join our alliance.”
The New England Council encourages its members who have recovered from COVID-19 to donate convalescent plasma. Additionally, social distancing measures have caused a decrease in regular blood donations, and those who have not had the disease are encouraged to donate blood. The Council applauds Takeda for their work in developing treatments to protect our most vulnerable and essential workers in this crisis. Learn more about the CoVig-19 Plasma Alliance and how to donate.